Owkin and Bristol Myers Squibb began a multi-year collaboration applying AI to clinical trial design, starting with cardiovascular disease.

BMS wanted more precise and efficient trials. Owkin applies machine learning to data from academic medical centres to optimise endpoint definitions, patient subgroups and treatment effect estimation. The page states $80 million in upfront and equity payments and potential milestones above $100 million; no trial results are given.

Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.

This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.